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Abstract Studies of [3H]glycerol turnover in phosphatidylcho-
line (PC) in platelets revealed two metabolic pools, a ‘low turn-
over PC’ in collagen-induced microparticles with speci¢c radio-
activity only 10% of that found in the ‘high turnover PC’ of
bulk platelet PC. Isolated organelle fractions of [3H]glycerol-
labelled platelets contained [3H]PC with speci¢c radioactivities
about 20% of that in membrane fractions. These results together
with studies on distribution of concanavalin A-FITC and GPlb,
a plasma membrane receptor, indicate that microparticles
formed during exocytosis are not simple vesiculations of plasma
membrane, but they seem rather to originate from a relatively
metabolically static membrane pool not accessible to extracel-
lular reagents. 0 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Membrane vesicles, referred to as microparticles ([1], re-
view), are shed from blood platelet probably in vivo and def-
initely in vitro upon aging under blood bank storage [2,3],
high shear £ow experiments [4] and agonist-induced, regulated
exocytosis [5,6]. While microparticle formation induced by age
or £ow is normally low, agonist-stimulated exocytosis in
platelets gives rise to rapid and abundant microparticle for-
mation [5,6]. For abundancy reasons, microparticles formed
by exocytosis agonists were used for these studies with the
reservation that they may have di¡erent biochemical charac-
teristics from those formed by other mechanisms.
Platelet microparticles play an important role in coagula-
tion by providing an extended catalytic surface for binding
and activation of speci¢c coagulation factors by surface ex-
posure of phosphatidylserine (PS) [5^15]. Vesiculation or bleb
formation on the cell surface accompanied by increased ex-
posure of PS on both platelets and microparticles has been the
basis for the accepted view that platelet microparticles are
formed by vesicular budding from the plasma membrane of
activated platelets.
In studies of phosphatidylcholine (PC) metabolism in plate-
lets, the incorporation of [3H]glycerol into PC of collagen-
induced microparticle membranes was found to be markedly
lower than into bulk platelet PC (this article). Platelets lack
nuclei and are formed by fragmentation from megakaryocytes
as mature cells with prepackaged organelles [16,17] and secre-
tory organelle resynthesis does not occur as in nucleated cells.
The low turnover of microparticle membrane PC compared to
bulk platelet PC led us to investigate secretory organelle mem-
branes for comparison. The speci¢c radioactivity of [3H]PC
after [3H]glycerol labelling was determined in resting platelets,
activated platelets, microparticles and isolated secretory or-
ganelles. The distributions of a native plasma membrane
marker, GPlb, and an extracellular labelling reagent, conca-
navalin A (ConA), were also studied in resting platelets, in
microparticles formed by exocytosis and in subcellular frac-
tions. These studies indicate that exocytosis-associated micro-
particles or vesicles resemble more closely intracellular organ-
elle membranes than intact platelets, measured as the total
platelet content of the various markers.
2. Materials and methods
2.1. [3H]Glycerol labelling and isolation of platelets
Blood was taken by venipuncture from non-medicated, healthy vol-
unteers into 0.15 vol. of ACD, courtesy of the blood bank at Hauke-
land Hospital. Platelet-rich plasma (PRP) and platelet isolation by gel
¢ltration were carried out as previously described [18]. [3H]Glycerol
(1.0 MBq/ml, DuPont NEN, Code NET 848) was added to PRP for
1 h at 22‡C before gel ¢ltration or washing by centrifugation in frac-
tionation studies. Calcium-free Tyrode’s solution containing 0.2% bo-
vine serum albumin and 5 mM glucose, pH 7.3, was used for gel
¢ltration, pH 6.5 for centrifugation. The platelet counts used were
about 4^5U108/ml.
2.2. ConA labelling of platelets
After [3H]glycerol incubation in PRP, platelets were washed once
by sedimentation with calcium-free Tyrode’s solution, pH 6.5, resus-
pended, incubated with 0.5^1 mg of ConA-FITC ((343235), Calbio-
chem) for 30 min at 22‡C and then washed again to remove excess
reagent. Concanavalin binding to membrane fractions was measured
by £uorescence in 0.1% Triton X-100 (excitation 495 nm, emission 525
nm).
2.3. Activation of labelled platelets
Activation with 20 Wg collagen/ml (Kollagen reagens Horm, Ny-
comed Hormon-Chemie, Munich, Germany) or thrombin receptor
agonist peptide (TRAP) 50 WM was carried out at 37‡C with stirring
(900 rpm) after addition of CaCl2 (4 mM). Aggregation was termi-
nated at 5 min by addition of PGE1 (25 WM) and the platelets were
centrifuged at 13 000UgU4 min at 4‡C and the supernatant saved as
the microparticle fraction. Only a negligible pellet which did not de-
tract from bulk supernatant analyses was found after a second cen-
trifugation at 13 000UgU30 min.
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2.4. Subcellular fractionation of platelets
Washed platelets were treated by metabolic inhibitors to prevent
secretion as described previously [19] and then lysed by ultrasonica-
tion (50 W on a Branson soni¢er B12, microtip probe) for three cycles
of 20 s each with 30 s cooling between each cycle. Residual platelets
and aggregated debris were removed by centrifugation at 1000UgU10
min and the organelle fraction sedimented at 10 000UgU10 min. The
pellet was washed once and the combined supernatants were centri-
fuged at 100 000UgU30 min to give a membrane fraction.
2.5. Lipid extraction and analysis
Total lipid extracts were prepared from 1 ml aliquots of control
platelet suspensions, aggregated platelets (resuspended in 1 ml 0.15 M
NaCl containing 25 WM PGE1 or supernatants from collagen-treated
platelets as described by Bligh and Dyer [20]. The dried lipids were
dissolved in 50 Wl chloroform and spotted on aluminum-backed silica
platelets (Merck article 5553, DC Alufolien Kieselgel 60). The plates
were chromatographed with chloroform/methanol/methylamine 20%
in H2O (60:36:10, v/v). [3H]PC was detected by Radioscanner Isomess
3000 Radio-TLC Analyzer (‘RITA’, Raytest) or PC mass was visual-
ized by I2 vapor. The PC spots were scraped, extracted from the silica
[21] and aliquots taken for scintillation counting and PC mass deter-
minations as Pi with a malachite green method [22].
2.6. Flow cytometry
Flow cytometric analysis was carried out as previously described
[23] with a FACSort £ow cytometer (Becton Dickinson, BDIS, San
Jose, CA, USA). The platelets were ¢xed in 0.2% formaldehyde in
PBS bu¡er 2 min after agonist addition; half of each sample was
labelled with CD42a-FITC (BDIS) and the other half with chicken
anti-human platelet-FITC (Biopool, Umea, Sweden). Gating on both
FITC and light scatter pro¢les identi¢ed platelets and microparticles,
5000 events per analysis in triplicate.
3. Results
3.1. [3H]Glycerol turnover in PC in platelets and in
microparticles
The speci¢c radioactivity of PC in resting, [3H]glycerol-la-
belled platelets was 476Q 155 dpm/nmol PC and 49.4Q 22
dpm/nmol PC in microparticles from collagen-stimulated
platelets (meansQ S.D., n=13). The mass of PC in ¢ve di¡er-
ent preparations of microparticles was 20.2 Q 12% (S.D.) of
that found in resting platelets, comparable to the 15^35% of
PF3 (phosphatidylserine) found in microparticles compared to
intact platelets reported by Sandberg et al. [6].
3.2. Distribution of ConA in platelets and in microparticles
The amount of concanavalin binding sites and £uorescence
label in microparticle membranes was only 6% that of resting
platelets, normalized per nmol PC (Table 1).
3.3. PC speci¢c radioactivity and distribution of ConA in
subcellular fractions
[3H]Glycerol-labelled platelets were fractionated as de-
scribed in Section 2 in order to compare the speci¢c radio-
activity of PC in intracellular organelles and in intact platelets
(Table 1). An aliquot of the same platelet suspension was
stimulated with collagen and the microparticle fraction was
analyzed for comparison with organelle membranes. The yield
and integrity of the isolated organelles were monitored by
assaying for the dense granules which constitute about 50%
of total platelet ADP+ATP [19]. The organelle fraction, which
includes dense and K-granules and lysosomes, contained
20.9Q 9.3% (S.D., n=4) of total platelet ATP/ADP or a
40% yield of dense granules. The concentration of adenine
nucleotides (nmol/mg protein) was 9.16Q 4.4 (S.D., n=4)
greater than in intact platelets, an 18-fold enrichment of dense
granules. The speci¢c radioactivity of the organelle PC was
17% of that of PC in intact platelets. In platelets preincubated
with ConA-FITC, the £uorescence per nmol PC of the organ-
elles was 23.8% of that of intact platelets. The latter results
Fig. 1. Flow cytometric analysis of resting and activated platelet
suspensions using chicken anti-human platelet antibody and CD42a.
See text for description.
Table 1
The third vertical data column gives the meansQS.D. for ¢ve fractionation preparations and the ¢fth column shows two of these experiments











Intact, resting platelets 39 988 67.9 555Q 56 (n=5) 60.6 0.870, 0.929
Organelles 1 535 17.6 94.4Q 16 (n=5) 3.57 0.203, 0.225
Membranes 25 141 61.9 431Q 24.5 (n=5) 32.4 0.523, 0.730
Microparticles from activated
plateletsb
889 25.1 36Q 4.1 (n=4) 1.38 0.055, 0.053
aThe total dpm, Pi and £uorescence, columns 1, 2 and 4, respectively, represent data from the ¢rst experiment with ConA-FITC shown in col-
umn 5. These data were not suited for statistical analysis because the number of platelets and the dpm varied with the preparation although
the speci¢c labelling was remarkably similar.
bThe microparticles were prepared by collagen activation of aliquots from the platelet suspensions that were fractionated and the values in col-
umns 1 and 2 were normalized to be comparable to the same total as the fractionated platelets in the ¢rst ConA experiment.
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serve as a measure of contamination of the organelle fraction
by extracellular membranes because the intracellular organ-
elles would not have been labelled by ConA. The membrane
fraction or 100 000Ug pellet had a PC speci¢c radioactivity
and a ConA-labelling somewhat lower than in intact platelets
(Table 1), probably because some surface labelling may have
been removed by the nagarse-protease pretreatment used in
the fractionation procedure [19].
3.4. Lactate dehydrogenase distribution
The 100 000UgU30 min pellet (microparticle fraction) from
the supernatant of a 1000UgU10 min preparation of colla-
gen-treated platelets contained about 1.3^1.4% of the lactate
dehydrogenase present in intact platelets. Almost no activity
was found in the 100 000Ug supernatant (cytoplasm plus
extracellular medium), indicating that no leakage of cytoplas-
mic constituents had occurred.
3.5. Distribution of GPlb as studied by £ow cytometry
The distribution of a plasma membrane collagen receptor,
GPlb, was probed with CD42a and compared with the distri-
bution of a polyclonal antibody raised in chickens to frozen
and thawed human platelets that interacts mainly with GPIIb/
IIIa (T. Lindahl, personal communication) present in platelet
K-granules and plasma membranes [24]. Fig. 1 shows cytomet-
ric analysis of resting (a, c) and TRAP-stimulated (b, d) plate-
lets. Panels b and d show the same ¢xed sample labelled with
anti-human platelet-FITC (b) or CD42a-FITC (d). Lower left
quadrants show microparticles and intact platelets appear at
the right. Microparticles showed almost no CD42a labelling
(d).
4. Discussion
Membranes of platelet microparticles formed following col-
lagen or TRAP stimulation of secretion are di¡erent from
whole platelet membranes and similar to isolated secretory
organelles with respect to [3H]glycerol turnover in PC and
distribution of ConA in prelabelled cells, microparticles and
subcellular organelles (Table 1). Exocytosis-induced micropar-
ticle formation occurred with no release of lactate dehydroge-
nase in contrast to that released with platelet vesiculation
during in vitro aging [25].
Flow cytometric experiments have also shown that GPlb
which is abundant on the surface of resting and activated
platelets was almost not present in agonist-induced micropar-
ticles compared to chicken anti-platelet antibody which labels
mostly GPIIb/IIIa (Fig. 1). A GPlb-positive, anti-platelet anti-
body-negative population of particles approximating the size
of, but not identical with, platelets labelled with the chicken
antibody was inexplicably elevated in TRAP-treated platelets
(Fig. 1d). The validity of GPlb as an exclusive plasma mem-
brane marker in platelets is controversial. Although some
GPlb appeared to be on granule membranes in histochemical
studies [26,27], little was found in isolated organelles com-
pared to GPIIb/IIIa which is present in both K-granules and
on the plasma membrane [24]. A recent article reported an
even distribution of GPlb on the platelet surface and in the
open canalicular system in resting platelets, but no claim was
made with regard to GPlb localization on organelle mem-
branes [28]. The work by Zdebska et al. [29] showed that
GPlb was present in platelets pelleted at 1000Ug and in a
10 000UgU10 min pellet, but that very much less GPlb/mg
protein was seen in smaller particles supports our ¢ndings.
The mechanism by which these intracellular membranes
reach the outside of intact cells has been problematic, but
the recent observations by Wang et al., which show that in
vacuole fusion in yeast cells the apposed membranes of the
fusing vesicles become detached and free within the new or-
ganelle, o¡er a plausible mechanism [30]. Compound exocy-
tosis, i.e. fusion of secretory organelles at the time of exocy-
tosis, is well-described in platelets as well as sightings of
membrane fragments within the fused organelles [30^33]. Re-
lease of membrane vesicles, exosomes, from dendrites, T-cells
and even platelets has been reported [34]. Heijnen et al. [35]
distinguished between microparticles and exosomes by density
and by the presence of GPlb on microparticles and its absence
on exosomes; although the relative amounts of GPlb on plate-
lets and microparticles were not shown. Microparticles with
di¡erent membrane properties can be formed by mechanisms
other than exocytosis, e.g. complement activation of normal
platelets [10] or Glanzmann’s thrombasthenia platelets [36]
resulted in microparticles profusely labelled with anti-GPlb.
Our results indicate that platelet microparticles in these ex-
periments represent intracellular organelle membranes which
serve as a catalytic platform for procoagulant factors. Exocy-
tosis has been considered to be primarily a general mechanism
for release of various soluble components, but regulated re-
lease of particulate membrane vesicles from cells apparently
also takes place and serves as an ‘extracellular signalling de-
vice’ (this article, [34,35,37^39]). However, our results do not
discriminate against the possibility that domains of organelle
membranes fused to the plasma membrane or other special
domains lacking the measured markers might form buds
which become detached extracellularly.
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